Adverse reactions to meglumine antimoniate in Brazilian inpatients with visceral leishmaniases: A case series.

WHAT IS KNOWN AND

OBJECTIVES

Adverse drug reactions (ADR) related to the treatment of visceral leishmaniasis (VL) can cause severe clinical complications. We report a case series of ADR in hospitalized VL patients on meglumine antimoniate (MA).

CASE DESCRIPTION: Seven cases of patients taking MA had at least one objective evidence for suspected ADR, including electrocardiographic, laboratory or clinical alteration.

WHAT IS NEW AND

CONCLUSION

Meglumine antimoniate is highly toxic. Adherence to treatment guidelines is important. Pharmacists working in multidisciplinary teams may contribute to early detection and management of MA therapy-related ADR.